Risk of Thrombosis Following the First Dose of ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Maintenance Hemodialysis: A Self-Controlled Case Series Study

References

• Salerno S, Messana JM, Gremel GW, et al. COVID-19 risk factors and mortality outcomes among medicare patients receiving long-term dialysis. JAMA Netw Open. 2021;4:e2135379. doi:10.1001/jamanetworkopen.2021.35379
   PubMed Web of Science ®Google Scholar
• Lai TS, Hsu CC, Lin MH, Wu VC, Chen YM. Trends in the incidence and prevalence of end-stage kidney disease requiring dialysis in Taiwan: 2010–2018. J Formos Med Assoc. 2022;121:S5–S11. doi:10.1016/j.jfma.2021.12.013
   PubMed Web of Science ®Google Scholar
• Lee JJ, Lin CY, Chiu YW, Hwang SJ. Take proactive measures for the pandemic COVID-19 infection in the dialysis facilities. J Formos Med Assoc. 2020;119:895–897. doi:10.1016/j.jfma.2020.03.022
   PubMed Web of Science ®Google Scholar
• Yen CC, Lin SY, Chen SC, Chiu YW, Chang JM, Hwang SJ. COVID-19 vaccines in patients with maintenance hemodialysis. J Pers Med. 2021;11:789. doi:10.3390/jpm11080789
   PubMed Web of Science ®Google Scholar
• Yang IN, Lu CL, Tang HJ, et al. Safety of ChAdOx1 NCoV-19 vaccination in patients with end-stage renal disease on hemodialysis. PLoS One. 2022;17:e0273676. doi:10.1371/journal.pone.0273676
   PubMed Web of Science ®Google Scholar
• Chen CY, Ye JJ, Huang TS, et al. Effective preventive strategies to prevent secondary transmission of COVID-19 in hemodialysis unit: the first month of community outbreak in Taiwan. Healthcare. 2021;9:1173. doi:10.3390/healthcare9091173
   Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi:10.1016/s0140-6736(20)32661-1
   PubMed Web of Science ®Google Scholar
• Michele MD, Kahan J, Berto I, et al. Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination. Circ Res. 2022;130:1187–1203. doi:10.1161/circresaha.122.319954
   PubMed Web of Science ®Google Scholar
• Buoninfante A, Andeweg A, Baker AT, et al. Understanding Thrombosis with Thrombocytopenia Syndrome after COVID-19 Vaccination. NPJ Vaccines. 2022;7:141. doi:10.1038/s41541-022-00569-8
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Pai PJ, McCracken JE, et al. Platelet Factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol. 2010;134:774–780. doi:10.1309/ajcpg0mnr5ngknfx
   PubMed Web of Science ®Google Scholar
• Arepally GM, Hursting MJ. Platelet Factor 4/Heparin Antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. J Thromb Thrombolysis. 2008;26:55–61. doi:10.1007/s11239-008-0217-y
   PubMed Web of Science ®Google Scholar
• Lin YL, Lin CY, Liu JH. Vaccine-Induced immune thrombotic thrombocytopenia presenting as a mimic of heparin-induced thrombocytopenia in a hemodialysis patient receiving ChAdOx1 NCoV-19 vaccine. Ren Fail. 2022;44:1131–1134. doi:10.1080/0886022x.2022.2098772
   Web of Science ®Google Scholar
• Kuo C, Tsai CC, Chen CA, Tsai YF, Chen YH. Anti-platelet factor 4/heparin antibody plays a significant role in progression of arterial stiffness among hemodialysis patients. Acta Cardiol Sin. 2017;33:188–194. doi:10.6515/acs20160818b
   PubMed Web of Science ®Google Scholar
• Liu CC, Chou LP, Chen TS, Chen CA, Tsai YF. Significant association of anti-platelet factor 4/heparin antibody with cardiovascular disease in hemodialysis patients: a longitudinal 7-year study. Int Urol Nephrol. 2018;50:2289–2297. doi:10.1007/s11255-018-2002-y
   PubMed Web of Science ®Google Scholar
• Lu HY, Liao KM. Increased risk of deep vein thrombosis in end-stage renal disease patients. BMC Nephrol. 2018;19:204. doi:10.1186/s12882-018-0989-z
   PubMedGoogle Scholar
• Ocak G, Vossen C, Rotmans J, et al. Venous and arterial thrombosis in dialysis patients. Thromb Haemost. 2011;106:1046–1052. doi:10.1160/th11-06-0422
   PubMed Web of Science ®Google Scholar
• Tsai MS, Lin MH, Lee CP, et al. Chang gung research database: a multi-institutional database consisting of original medical records. Biomed J. 2017;40:263–269. doi:10.1016/j.bj.2017.08.002
   PubMed Web of Science ®Google Scholar
• Shao S, Lai EC, Huang T, et al. The chang gung research database: multi‐institutional real‐world data source for traditional Chinese medicine in Taiwan. Pharmacoepidem Drug Safe. 2021;30:652–660. doi:10.1002/pds.5208
   PubMed Web of Science ®Google Scholar
• Shao SC, Su YC, Lai ECC, et al. Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: a multi-institutional cohort study in Taiwan. Diabetes Metab. 2022;48:101318. doi:10.1016/j.diabet.2022.101318
   PubMed Web of Science ®Google Scholar
• Su YC, Hung JH, Chang KC, et al. Comparison of sodium-glucose cotransporter 2 inhibitors vs glucagonlike peptide-1 receptor agonists and incidence of dry eye disease in patients with type 2 diabetes in Taiwan. JAMA Netw Open. 2022;5:e2232584. doi:10.1001/jamanetworkopen.2022.32584
   PubMed Web of Science ®Google Scholar
• Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515. doi:10.1136/bmj.i4515
   PubMed Web of Science ®Google Scholar
• Yen CC, Wei KC, Wang WH, Huang YT, Chang YC. Risk of guillain-barré syndrome among older adults receiving influenza vaccine in Taiwan. JAMA Netw Open. 2022;5:e2232571. doi:10.1001/jamanetworkopen.2022.32571
   PubMed Web of Science ®Google Scholar
• Snell J. SARS-CoV-2 infection and its association with thrombosis and ischemic stroke: a review. Am J Emerg Medicine. 2021;40:188–192. doi:10.1016/j.ajem.2020.09.072
   PubMed Web of Science ®Google Scholar
• Gorog DA, Storey RF, Gurbel PA, et al. Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium. Nat Rev Cardiol. 2022;19:475–495. doi:10.1038/s41569-021-00665-7
   PubMed Web of Science ®Google Scholar
• Hsieh MT, Hsieh CY, Tsai TT, Wang YC, Sung SF. Performance of ICD-10-CM diagnosis codes for identifying acute ischemic stroke in a national health insurance claims database. Clin Epidemiol. 2020;12:1007–1013. doi:10.2147/clep.s273853
   PubMed Web of Science ®Google Scholar
• Hsieh MT, Hsieh CY, Tsai TT, Sung SF. Validation of stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage on Taiwan’s national health insurance claims data. Clin Epidemiol. 2022;14:327–335. doi:10.2147/clep.s353435
   PubMed Web of Science ®Google Scholar
• Liao SC, Shao SC, Lai ECC, Lin SJ, Huang WI, Hsieh CY. Positive predictive value of ICD-10 codes for cerebral venous sinus thrombosis in Taiwan’s national health insurance claims database. Clin Epidemiol. 2022;14:1–7. doi:10.2147/clep.s335517
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 Vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374(1931). doi:10.1136/bmj.n1931
   Google Scholar
• Higgins H, Andrews N, Stowe J, et al. Risk of thrombosis with thrombocytopenia syndrome after COVID‐19 vaccination prior to the recognition of vaccine‐induced thrombocytopenia and thrombosis: a self‐controlled case series study in England. Res Pract Thromb Haemost. 2022;6:e12698. doi:10.1002/rth2.12698
   PubMed Web of Science ®Google Scholar
• Krzywicka K, Munckhof A, Kammen MS, et al. Age-stratified risk of cerebral venous sinus thrombosis after SARS-CoV-2 vaccination. Neurology. 2022;98:e759–e768. doi:10.1212/wnl.0000000000013148
   PubMed Web of Science ®Google Scholar
• Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. New Engl J Med. 2021;385:1680–1689. doi:10.1056/nejmoa2109908
   PubMed Web of Science ®Google Scholar